Tags

Type your tag names separated by a space and hit enter

Lithium, a potential protective drug in Alzheimer's disease.
Neurodegener Dis. 2008; 5(3-4):247-9.ND

Abstract

Alzheimer's disease is characterized by the presence of two histopathological aberrant structures, the senile plaques and the neurofibrillary tangles. The main component of these tangles is the cytoskeletal protein tau in hyperphosphorylated form. Since a main tau kinase is glycogen synthase kinase 3 (GSK-3), the use of specific GSK-3 inhibitors, like lithium, could be a potential therapy in Alzheimer's disease. In this short article, we have done a review on tau phosphorylation in Alzheimer's disease and other tauopathies, and on the inhibition of kinases like GSK-3, involved in tau modification.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Engel T
Centro de Biología Molecular Severo Ochoa, CSIC-UAM, Facultad de Ciencias, Universidad Autónoma de Madrid, Madrid, Spain.
Goñi-Oliver P
No affiliation info available
Gómez de Barreda E
No affiliation info available
Lucas JJ
No affiliation info available
Hernández F
No affiliation info available
Avila J
No affiliation info available

MeSH

Alzheimer DiseaseAnimalsGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaHumansLithium CompoundsNeuroprotective Agents

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18322403

Citation

Engel, T, et al. "Lithium, a Potential Protective Drug in Alzheimer's Disease." Neuro-degenerative Diseases, vol. 5, no. 3-4, 2008, pp. 247-9.
Engel T, Goñi-Oliver P, Gómez de Barreda E, et al. Lithium, a potential protective drug in Alzheimer's disease. Neurodegener Dis. 2008;5(3-4):247-9.
Engel, T., Goñi-Oliver, P., Gómez de Barreda, E., Lucas, J. J., Hernández, F., & Avila, J. (2008). Lithium, a potential protective drug in Alzheimer's disease. Neuro-degenerative Diseases, 5(3-4), 247-9. https://doi.org/10.1159/000113715
Engel T, et al. Lithium, a Potential Protective Drug in Alzheimer's Disease. Neurodegener Dis. 2008;5(3-4):247-9. PubMed PMID: 18322403.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lithium, a potential protective drug in Alzheimer's disease. AU - Engel,T, AU - Goñi-Oliver,P, AU - Gómez de Barreda,E, AU - Lucas,J J, AU - Hernández,F, AU - Avila,J, Y1 - 2008/03/06/ PY - 2008/3/7/pubmed PY - 2008/5/16/medline PY - 2008/3/7/entrez SP - 247 EP - 9 JF - Neuro-degenerative diseases JO - Neurodegener Dis VL - 5 IS - 3-4 N2 - Alzheimer's disease is characterized by the presence of two histopathological aberrant structures, the senile plaques and the neurofibrillary tangles. The main component of these tangles is the cytoskeletal protein tau in hyperphosphorylated form. Since a main tau kinase is glycogen synthase kinase 3 (GSK-3), the use of specific GSK-3 inhibitors, like lithium, could be a potential therapy in Alzheimer's disease. In this short article, we have done a review on tau phosphorylation in Alzheimer's disease and other tauopathies, and on the inhibition of kinases like GSK-3, involved in tau modification. SN - 1660-2862 UR - https://www.unboundmedicine.com/medline/citation/18322403/Lithium_a_potential_protective_drug_in_Alzheimer's_disease_ DB - PRIME DP - Unbound Medicine ER -